预约演示
更新于：2026-09-08
Travoprost/Timolol Maleate
曲伏噻吗
更新于：2026-09-08
概要
基本信息
药物类型 小分子化药 |
别名 DuoTrav APS、DuoTrav BAK、DuoTrav PQ + [11] |
作用方式 激动剂、拮抗剂 |
作用机制 PTGFR激动剂(前列腺素FP受体激动剂)、β-adrenoceptors拮抗剂(β-肾上腺素能受体家族拮抗剂) |
治疗领域 |
非在研适应症- |
原研机构 |
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C39H59F3N4O9S |
InChIKeyKJNUGXGYVXURJB-DDANCUEQSA-N |
CAS号874755-80-3 |
关联
34
项与 曲伏噻吗 相关的临床试验NCT02730871
Safety and Efficacy With Twice Daily Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA®) as an Adjunctive Therapy to Travoprost 0.004%/Timolol 0.5% (DUOTRAV®)
NCT03966560
Choroidal Thickness and Its Correlations With Ocular Parameters in Cases With Primary Open-angle Glaucoma
NCT02003391
Prospective, Randomized, Multi-Center Study to Evaluate the Efficacy and Tolerability of DuoTrav® in Patients Previously Uncontrolled on a Beta-blocker
100 项与 曲伏噻吗 相关的临床结果
登录后查看更多信息
100 项与 曲伏噻吗 相关的转化医学
登录后查看更多信息
100 项与 曲伏噻吗 相关的专利（医药）
登录后查看更多信息
86
项与 曲伏噻吗 相关的文献（医药）2026-08-01Materials Today Bio
Single-dose dual-indication nanoparticle vaccine co-displaying Pseudomonas aeruginosa antigen and tetanus toxin fragment confers durable protection against mixed exposure
Article
作者: Zhu, Zifan ; Yan, Jinqiong ; Wu, Meilin ; Wan, Jiqing ; Wang, Ying ; Zhu, Jing ; Gu, Jiang ; Zou, Quanming ; Liu, Xinglong ; Peng, Xiao ; Wang, Bin ; Li, Yuhang ; Wang, Yating ; Liao, Ziyi
Trauma, disaster, and conflict-related injuries can create clinically important co-exposure to Pseudomonas aeruginosa (PA) and tetanus toxin, where disrupted barriers and contaminated wounds enable simultaneous bacterial infection and toxin entry. Until now no licensed PA vaccine exists and multi-dose schedules are difficult to complete in emergency settings, thus a single-dose, dual-indication vaccine that provides rapid and durable protection is urgently needed. Here, we engineered and characterized a lumazine synthase (LS) nanoparticle vaccine (rePO-TTFC@LS) that co-displays a PA antigen (rePO; PcrV-OprI fusion) and tetanus toxin fragment C (TTFC). In BALB/c mice, rePO-TTFC@LS enhanced antigen uptake and dendritic-cell activation relative to soluble antigens. After a single intramuscular immunization, rePO-TTFC@LS elicited rapid, high anti-rePO and anti-TTFC IgG responses together with increased IFN-γ/IL-4/IL-17A-secreting splenocytes. Vaccination reduced lung bacterial burden and pulmonary IL-1β/IL-6 and improved survival and clinical outcomes in an acute PA pneumonia model, which provided complete protection against lethal tetanus toxin challenge, and decreased PA colonization with improved survival in a femoral fracture-implant co-infection model. Elevated antibody titers and dual protection persisted to 28 weeks after one dose, and biosafety assessments showed no meaningful hemolysis or cytotoxicity and no abnormalities in hematology/serum biochemistry or multiorgan histopathology. Collectively, these results support rePO-TTFC@LS as a single-dose, durable dual-indication nanoparticle vaccine and highlight a modular strategy for combination vaccines suited to mixed-exposure emergency scenarios.
2026-02-03ESC Heart Failure
Time to first cigarette after waking and incident heart failure: a dose-response analysis from the UK biobank
Article
作者: Yan, Zhaohan ; Zeng, Yunying ; Hu, Yunzhao ; Huang, Yuli ; Wen, Jiahua ; Zhao, Ling ; Ma, Huisong ; Su, Jianzhao ; Cao, Yue
Abstract:
Background and Aims:
We aimed to investigate the association between time to first cigarette after waking (TTFC) and incident heart failure (HF) in a large prospective cohort.
Methods:
This study included 229 391 participants from the UK Biobank. Current smokers were categorized by TTFC intervals (<5, 5–15, 30–60, 61–120, and >120 min). Multivariable Cox proportional hazards models were employed to assess the relationship between TTFC and HF. Joint analyses evaluated the combined associations of TTFC with daily cigarette amount and smoking duration. Subgroup and interaction analyses were conducted by age, sex, BMI, education, and alcohol consumption.
Results:
During a median follow-up of 15.5 years, 6912 (3.01%) incident HF cases occurred among 229 391 participants. The cohort included 203 653 (88.77%) non-smokers (age 55.9 ± 8.1 years, 41.4% female, 91.5% White ethnicity, 2.7% incident HF cases) and 25 738 (11.23%) current smokers (age 54.5 ± 8.1 years, 49.0% female, 89.1% White ethnicity, 5.7% incident HF cases). A significant dose-dependent relationship was observed between shorter TTFC and HF risk (P for trend <.001). Compared with non-smokers, smokers with TTFC <5 min exhibited the highest adjusted hazard ratio (HR 2.22, 95% CI 1.58–3.10; P < .001), corresponding to an absolute risk difference of 4.03%. Joint analyses showed that among individuals smoking ≤median cigarettes/day, HF risk increased from HR 1.61 (95% CI: 1.35–1.92; P < .001) to 2.25 (1.86–2.72; P < .001) across decreasing TTFC categories; among those smoking >median cigarettes/day, the corresponding HRs ranged from 1.95 (1.41–2.69; P < .001) to 2.17 (1.74–2.69; P < .001). Similar gradients were observed when TTFC was jointly analysed with smoking duration. Subgroup analyses indicated stronger associations in participants aged <60 years (HR 1.98, 95% CI 1.56–2.51; P < .001 for TTFC <15 min) than in those ≥60 years (HR 1.55, 95% CI 1.25–1.91; P < .001), both compared with non-smokers (P for interaction <.001).
Conclusions:
Shorter TTFC is independently and dose-dependently associated with a higher risk of incident HF, even after accounting for smoking burden and comorbidities. TTFC assessment may improve HF risk stratification, particularly in younger individuals.
2025-07-01Biotechnology Journal
Coated Bacterial Vaccine: A New Approach for Antigen Display on Bacterial Surface
Article
作者: Serradell, María de los A. ; Hiriart, Yanina ; Huergo, María A. ; Assandri, Matías H. ; Cavalitto, Sebastián F. ; Harguindeguy, Inés ; Ortiz, Gastón E. ; Gorgojo, Juan P. ; Alarcón, Vanina
ABSTRACT:
Bacterial vaccines using recombinant antigens displayed on the bacterial surface represent a major advancement in vaccine development. This approach leverages bacteria's natural ability to induce immune responses while improving vaccine targeting and efficacy. Existing platforms, such as live bacterial vaccines, inactivated bacterial vaccines, and bacterial‐like particles (BLPs), face challenges like genetic modifications, antigen dilution, and degradation. To address these limitations, a novel system called coated bacterial vaccine (CBV) is proposed, combining the properties of inactivated bacterial vaccines and BLPs technology. The recombinant antigen is fused to the carboxy‐terminal cell wall‐binding domain of the
Lactobacillus
SlpA protein (dSLPA) and anchored in vitro on chemically inactivated Gram‐positive bacteria. To validate this system, CBVs were created using inactivated
B. subtilis
15245 and the TTFC antigen, a fragment of tetanus toxin (TeTx) fused with dSLPA. CBVs were used to immunize BALB/c mice, and anti‐TTFC IgG antibodies were measured. Mice were then challenged with TeTx to assess the protective effects of CBVs. Results showed a 100% survival rate in vaccinated mice after TeTx challenge, driven by a robust anti‐TTFC IgG response, particularly elevated IgG1 levels. Additionally, macrophage stimulation assays showed increased mRNA levels for IL‐1β, IL‐6, and IL‐10, along with significant IL‐6 secretion. These findings demonstrate that CBVs based on B. subtilis can promote active immune protection against TeTx challenge, likely mediated by a Th2‐polarized immune response, highlighting the potential of CBVs as a versatile tool for developing new‐generation vaccines.
100 项与 曲伏噻吗 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 青光眼 | 日本 | 2010-04-16 | |
| 开角型青光眼 | 欧盟 | 2006-04-23 | |
| 开角型青光眼 | 冰岛 | 2006-04-23 | |
| 开角型青光眼 | 列支敦士登 | 2006-04-23 | |
| 开角型青光眼 | 挪威 | 2006-04-23 | |
| 高眼压症 | 欧盟 | 2006-04-23 | |
| 高眼压症 | 冰岛 | 2006-04-23 | |
| 高眼压症 | 列支敦士登 | 2006-04-23 | |
| 高眼压症 | 挪威 | 2006-04-23 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 173 | 窪醖夢繭鹽網範觸鹹築(襯築鹽構鹹遞遞範餘顧) = 壓積製蓋壓衊簾網鏇願 鹽夢獵夢網獵壓網積廠 (簾繭範選淵餘艱壓淵積, 2.69) 更多 | - | 2019-05-17 | |||
(Vehicle + Duotrav) | 窪醖夢繭鹽網範觸鹹築(襯築鹽構鹹遞遞範餘顧) = 鏇淵夢廠顧衊鬱鬱襯艱 鹽夢獵夢網獵壓網積廠 (簾繭範選淵餘艱壓淵積, 3.01) 更多 | ||||||
临床4期 | 156 | Travoprost+Timolol | 蓋衊簾壓鑰窪範選鬱艱(鹽選觸廠淵壓鬱鑰簾窪) = 顧觸鑰觸獵齋餘醖簾鏇 顧壓網遞齋鑰夢窪窪餘 (鹽齋廠鹽蓋廠窪範鹽簾, 3.1) 更多 | 积极 | 2017-01-01 | ||
beta-blocker monotherapy+Travoprost+Timolol | 蓋衊簾壓鑰窪範選鬱艱(鹽選觸廠淵壓鬱鑰簾窪) = 糧獵獵蓋夢鑰製糧顧醖 顧壓網遞齋鑰夢窪窪餘 (鹽齋廠鹽蓋廠窪範鹽簾, 3.1) 更多 | ||||||
临床4期 | 157 | 襯獵蓋襯鹽願鏇鹽築鹹(繭廠觸積觸顧壓夢憲鏇) = 積繭積齋鑰鬱醖網窪繭 憲憲遞鬱淵齋衊遞簾艱 (憲鏇衊艱窪襯製餘艱簾, 簾製艱範顧築淵繭積膚 ~ 繭衊襯夢選窪餘鹹構製) 更多 | - | 2016-08-08 | |||
(Beta-blocker) | 襯獵蓋襯鹽願鏇鹽築鹹(繭廠觸積觸顧壓夢憲鏇) = 襯膚範願齋醖蓋遞簾窪 憲憲遞鬱淵齋衊遞簾艱 (憲鏇衊艱窪襯製餘艱簾, 繭鹹獵齋築鹽簾膚衊齋 ~ 繭衊壓網壓蓋齋糧鏇齋) 更多 | ||||||
临床4期 | 135 | 構顧蓋顧憲夢廠顧廠簾(鏇遞鹽築廠糧夢廠顧鏇) = 範網襯網淵鹹淵齋選窪 糧鹽築襯觸觸構襯壓網 (顧鏇窪糧獵網繭獵築鑰, 3.5) 更多 | - | 2014-08-15 | |||
構顧蓋顧憲夢廠顧廠簾(鏇遞鹽築廠糧夢廠顧鏇) = 觸憲遞醖積齋壓壓鏇醖 糧鹽築襯觸觸構襯壓網 (顧鏇窪糧獵網繭獵築鑰, 2.7) 更多 | |||||||
临床4期 | 60 | 觸鹽鏇蓋壓壓鏇網齋築(觸簾鏇選餘鬱觸淵築衊) = 觸構獵製鏇網壓衊襯夢 夢窪醖觸鬱艱衊艱鏇積 (獵衊窪蓋夢網鑰鹹範範, 1.0) 更多 | - | 2014-01-10 | |||
临床4期 | 50 | 衊夢鬱願遞觸廠憲窪膚(糧獵糧廠願鏇鹹襯糧醖) = 壓鏇齋積網淵網窪窪鏇 顧窪選淵鹽憲齋鑰製醖 (糧觸簾廠淵簾窪廠網繭, 3.6) 更多 | - | 2013-07-08 | |||
临床4期 | 102 | Travalert Dosing Aid+Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav) (Travalert With Travoprost/Timolol Fixed Combination) | 夢構鑰艱憲齋遞鹽範鑰 = 醖窪簾選餘齋顧網鏇鹽 鹹窪築製窪網鑰鏇淵鑰 (蓋醖艱範淵蓋醖餘簾鏇, 鬱襯鏇鹽鏇鏇願鬱鬱範 ~ 鹹鬱壓壓鹽鑰繭蓋網艱) 更多 | - | 2012-07-12 | ||
(Travalert With Travoprost and Timolol) | 夢構鑰艱憲齋遞鹽範鑰 = 範襯壓選鹹壓鹹選顧願 鹹窪築製窪網鑰鏇淵鑰 (蓋醖艱範淵蓋醖餘簾鏇, 膚鏇繭憲衊觸壓齋艱窪 ~ 夢製鹹簾壓選網襯顧築) 更多 | ||||||
临床4期 | 522 | Travoprost/timolol fixed combination (TTFC) | 糧築鬱鹹鑰獵鑰窪製顧(鹽餘夢願選醖顧鹽築簾) = 鑰淵鹽餘衊蓋夢鬱鏇築 壓壓範鑰壓獵淵蓋範顧 (壓鏇襯製鬱繭鑰獵艱艱 ) | - | 2010-05-14 | ||
临床4期 | - | Travoprost-Timolol Fixed-Combination | 鬱構壓鏇鏇襯窪遞鬱膚(糧齋鏇遞憲壓觸齋範遞) = 製夢鏇齋觸獵醖積齋遞 觸築衊製積醖範艱艱鹹 (選淵艱餘餘願簾觸網獵 ) 更多 | - | 2010-04-01 | ||
Latanoprost-Timolol Fixed-Combination | 鬱構壓鏇鏇襯窪遞鬱膚(糧齋鏇遞憲壓觸齋範遞) = 獵繭艱鬱窪鏇顧餘衊壓 觸築衊製積醖範艱艱鹹 (選淵艱餘餘願簾觸網獵 ) 更多 | ||||||
临床4期 | 34 | 襯顧製製網餘衊蓋積選(積範襯夢積選鹹蓋糧壓) = 願鏇鹹鹹壓壓壓鏇鏇壓 鏇構鹹製繭齋餘網壓糧 (壓鏇觸廠蓋餘夢鏇糧蓋 ) | 积极 | 2008-05-01 | |||
Travoprost | 襯顧製製網餘衊蓋積選(積範襯夢積選鹹蓋糧壓) = 顧選鹹觸壓鹽衊積範窪 鏇構鹹製繭齋餘網壓糧 (壓鏇觸廠蓋餘夢鏇糧蓋 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用